Dr. Pattee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2631 S 70th St
Lincoln, NE 68506Phone+1 402-483-7226Fax+1 402-483-5440
Education & Training
University of ColoradoResidency, Neurology, 1987 - 1990
Creighton University School of Medicine (Omaha)Internship, Internal Medicine, 1986 - 1987
McGovern Medical School at UTHealthClass of 1986
Certifications & Licensure
NE State Medical License 1991 - 2026
CO State Medical License 1988 - 2005- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Clinical Trial Nuedexta in Subjects With ALS Start of enrollment: 2013 Apr 01
- Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- 127 citationsBulbar and speech motor assessment in ALS: Challenges and future directionsJordan R. Green, Yana Yunusova, Mili S. Kuruvilla, Jun Wang, Gary L. Pattee
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2013-11-01 - 36 citationsSpeaking rate effects on articulatory pattern consistency in talkers with mild ALS.Antje S. Mefferd, Gary L. Pattee, Jordan R. Green
Clinical Linguistics & Phonetics. 2014-10-08 - 64 citationsCommunication Effectiveness of Individuals with Amyotrophic Lateral Sclerosis.Laura J. Ball, David R. Beukelman, Gary L. Pattee
Journal of Communication Disorders. 2004-05-01
Journal Articles
- Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral SclerosisSabrina Paganoni, Michael A Elliott, Samuel Maiser, Margaret A Owegi, Stephen A Goutman, Carlayne E Jackson, Jeffrey D Rothstein, Edward J Kasarskis, Liberty Jenkins, ..., The New England Journal of Medicine
Press Mentions
Mitsubishi Tanabe Pharma America Announces 48-Week Results from Global, Open-Label, Phase 3 Trial of RADICAVA ORS® (Edaravone) in ALSFebruary 27th, 2023- Alliance Backs SLE Research by Minority ScientistsJune 14th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
